Christopher Stevens serves as Chief Operating Officer at Rocket Pharmaceuticals Inc., a multi-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. In this pivotal role, he oversees all operational functions, including technical operations, manufacturing, supply chain management, quality assurance, and CMC (chemistry, manufacturing, and controls) activities. His leadership ensures the seamless execution of Rocket's pipeline, from clinical-stage programs like RP-L102 for Fanconi anemia to commercial readiness, driving the company's mission to deliver transformative therapies to patients worldwide. With over 25 years of experience in the biopharmaceutical industry, Stevens brings a proven track record in scaling complex manufacturing processes for biologics, cell, and gene therapies. Prior to joining Rocket in 2021, he was Executive Vice President and Head of Technical Operations at bluebird bio, where he spearheaded the build-out of end-to-end manufacturing capabilities, supporting the FDA approvals of ZYNTEGLO and SKYSONA—the first gene therapies for beta-thalassemia and cerebral adrenoleukodystrophy, respectively. Earlier, as Vice President of Manufacturing at Genzyme Corporation (now Sanofi), he managed global production of enzyme replacement therapies, optimizing operations for products like Cerezyme and Fabrazyme. Stevens' achievements include pioneering scalable lentiviral vector production platforms and navigating stringent regulatory landscapes to accelerate therapy development. His strategic vision has consistently enhanced operational efficiency, reduced costs, and ensured supply chain resilience, positioning Rocket Pharmaceuticals for sustained growth and successful commercialization in the competitive gene therapy space.